Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide and Everolimus in Castrate-Resistant Prostate Cancer
NCT01313559Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2011
- Primary completion
- Sep 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jun 2011; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01313559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313559.